Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
39,573,104
-
Share change
-
+5,122,724
-
Total reported value
-
$85,081,538
-
Put/Call ratio
-
21%
-
Price per share
-
$2.15
-
Number of holders
-
28
-
Value change
-
+$11,162,086
-
Number of buys
-
13
-
Number of sells
-
13
Institutional Holders of CTI BIOPHARMA CORP - COM (CTIC) as of Q3 2020
As of 30 Sep 2020,
CTI BIOPHARMA CORP - COM (CTIC) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,573,104 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, NEA Management Company, LLC, BVF INC/IL, CAXTON CORP, Stonepine Capital Management, LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., Verition Fund Management LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
28
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.